Beta Bionics, Inc. Common Stock Total Liabilities
Beta Bionics, Inc. Common Stock total liabilities. Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has total liabilities worth $36.02 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BBNX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Beta Bionics, Inc. Common Stock (2022–2025)
Total liabilities of Beta Bionics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Beta Bionics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Beta Bionics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Beta Bionics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XiAn Tian He Defense Technology Co Ltd
SHE:300397
|
China | CN¥1.32 Billion |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
China | CN¥6.62 Billion |
|
Guangdong Wencan Die Casting Co Ltd
SHG:603348
|
China | CN¥5.65 Billion |
|
Zhejiang Shengyang Science
SHG:603703
|
China | CN¥1.28 Billion |
|
Guilin Layn Natural Ingredients Corp
SHE:002166
|
China | CN¥1.85 Billion |
|
Friend Co Ltd
SHG:605050
|
China | CN¥4.13 Billion |
|
China Resources and Environment Co Ltd
SHG:600217
|
China | CN¥2.24 Billion |
|
Klaveness Combination Carriers ASA
OL:KCC
|
Norway | Nkr372.74 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Beta Bionics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Beta Bionics, Inc. Common Stock (BBNX) total assets.
Liquidity & Leverage Metrics
Beta Bionics, Inc. Common Stock Total Liabilities Ratios Explained
Beta Bionics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beta Bionics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $41.13 Million | -44.14% |
| 2024-12-31 | $73.63 Million | +43.16% |
| 2023-12-31 | $51.43 Million | -74.98% |
| 2022-12-31 | $205.56 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more